Merck Receives EU Approval for Keytruda-Padcev Combination in Bladder Cancer

Merck has received marketing authorization from the European Commission for the combination therapy of Keytruda (pembrolizumab) and Padcev (enfortumab vedotin) for adult patients with previously untreated unresectable or metastatic urothelial carcinoma. This approval is based on positive clinical data and allows the combination to be used across the European Union, expanding treatment options for bladder cancer patients.